Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Open Angle Glaucoma or Ocular HypertensionA Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular HypertensionA Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.Safety and Intraocular Pressure (IOP) Lowering Efficacy of Low Dose TravoprostEarly Diagnosis, Pathogenesis and Progression of Open Angle GlaucomaNon Interventional Study in Patients With Open Angle Glaucoma and/or Ocular Hypertension Treated With XALATAN®MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)Neurovascular Coupling in Eyes of Glaucoma PatientsUtility of Heidelberg Retina Tomograph in Monitoring Glaucoma ProgressionStudy of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or GlaucomaStudy of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular HypertensionSafety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular HypertensionBimatoprost Versus Travoprost at Cairo UniversitySafety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular HypertensionThe Performances of Spectral Domain Optical Coherence Tomography (OCT) for Distinguishing Glaucomatous EyesPatient Preference Comparison of AZARGA Versus COSOPT in Patients With GlaucomaEfficacy of Selective Laser Trabeculoplasty in Patients Under Treatment With Topical ProstaglandinesEfficacy of Selective Laser Trabeculoplasty in Pseudophakic PatientsEfficacy of Changing to TRAVATAN® From Prior TherapyTravacom Post Marketing Surveillance StudyAssessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)Travoprost 3-Month Safety and Efficacy StudyThree Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%A Study of GANFORT® UD in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT) in a Medical SettingInvestigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension GlaucomaIntraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked StudyAdherence Assessment With Travalert Dosing AidTolerability, Safety and Efficacy of SAD448 in Subjects With Ocular HypertensionTravoprost 0.004%/Timolol 0.5% Versus Latanoprost 0.005%/Timolol in Chinese Patients With Open-Angle Glaucoma or Ocular HypertensionSafety and Efficacy Study of DE-104 Ophthalmic Solution to Treat Open-angle Glaucoma or Ocular HypertensionOral Acetazolamide, Brimonidine Tartarate, and Anterior Chamber Paracentesis for Ocular Hypertension Control After Intravitreal BevacizumabSafety and Efficacy Study of DuoTrav APS Versus DuoTravA Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 StudyA Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 StudyPhase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular HypertensionComparison of the Effects of Two Glaucoma Drugs Over 24 Hours (0507A-137)(COMPLETED)Effects of Prostaglandin Analogue Washout Following Long-term Therapy in Adults With Primary Open Angle GlaucomaStudy of Changes in Retrofoveolar Choroidal Thickness During Aerobic ExerciseBREMEN Eye Drops Versus Combigan and Azopt for Open-angle Glaucoma or Intraocular HypertensionStudy of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
P1050
Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular PressureFixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials.Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.Development of ocular hypertension secondary to tamponade with light versus heavy silicone oil: A systematic review.Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trialsThe Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies.Role of dopaminergic receptors in glaucomatous disease modulation.Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis.Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension.Effect of systemic antihypertensives on change in intraocular pressure after initiating topical prostaglandins for primary open-angle glaucomaOphthalmologic manifestations in Taiwanese patients with mucopolysaccharidoses
P921
Q61862150-1FBC5C80-9D6C-4B79-B8DD-35578BC43958Q61894459-BD202B26-9FA0-4F5A-BB7E-8AC9BE75059FQ61915097-F46DC17B-197E-49F9-AF46-63039C4B3CACQ61915268-5CB445CD-39D4-409F-9275-2810FDF621F7Q61917616-74116D85-65FD-401E-8A8D-97C5855ECDB6Q61918442-96A74918-1367-4AAB-A569-4EE221D2ED25Q61921119-22EA8BF6-B1C8-4CC7-BE3D-53FECF9569FEQ61921156-70A77702-7811-4299-9638-9F3B54779B94Q61921548-B15E44B6-E7EA-43B1-A16D-5FB3EC96F786Q61924808-499E14A5-01A0-4E66-BB6A-2BDE421532E8Q61932880-B2FC42A4-AA64-4F11-9F37-E06CE6C92B5AQ61936175-FA05513B-3DE4-4B4A-9581-13C26C67D711Q61936957-000B3482-7A02-4098-A4CB-428B44562B37Q61938980-4798600A-9254-499C-A8D4-FAC11DB2F315Q61939136-983DE666-87F3-46D6-AFC2-37D04DAF206AQ61955591-210E4D10-E9E5-47F6-8D76-9600FAEA9432Q61956181-30A4DF11-8C8F-4275-B752-EEF805E9F732Q61956191-A415127A-EF73-4F4C-87E2-B366C6B2D366Q61956239-2781B59B-C068-4DD5-9FC2-5CD3EBE2CC27Q61956241-CCAE163E-DA09-4A48-A261-7F4172756DC8Q61956731-271E3B0D-44AE-4421-A2C5-83D28DA11236Q61966818-0709C3C7-1F2C-4180-8767-4377DE2E7740Q61967154-34E81E92-ED72-49F9-994C-CCB092A835D4Q61969224-03F5DB76-2060-4A75-9626-D39EEAB70EC9Q61969713-64835BF3-24C5-4AB8-ACD0-B629084E9116Q61974937-0A80328F-9133-47F7-A09D-EE82FE946FDCQ61979589-A3DB1EA9-7E95-4626-8AD4-B2D695010B4AQ61980174-55B736A4-1DB8-4A19-9BD7-8D67C38D39F8Q61980462-F2AF31EA-986D-4659-8336-A2BEFD45C75EQ61980765-4943A5BB-9F77-44D6-9870-FF8F1B73B189Q61981125-56995191-0C6D-4945-9C95-E59F46739E29Q61981318-B41CF8F2-1B98-4C3B-9925-DC1067BEF465Q62054065-58C03826-0C06-42E9-A6D8-AB05D0A1CC58Q62054066-77E6E8E1-BDDD-4743-80E0-24854CAB9F64Q62062590-1F6069A2-6F6E-4DC6-BEB8-F091CE4CA7D8Q62105564-CF445BA3-5E28-4634-B6A5-96BE065BD017Q62814746-287E9C38-D2D9-4F0D-BE2A-94E5CF6BEE95Q62815528-319DB2DB-6D3C-4BA4-80C9-6152E4312483Q63011543-6C3B9E40-BA35-48F9-828F-90CB36AC4526Q63011940-39995810-377B-4A66-BF67-A9C37946BB2B
P1050
Q2193376-5463C387-5645-4756-8111-D2B4C5160FE3Q2393348-C5D10814-6611-45A4-9B79-A0DA46B1942CQ27078867-85F6B232-7769-4503-BF78-B119EB77D6BCQ27106078-EB6328C2-BAD6-4492-8103-E95B1A1A4C49Q27280492-1923D328-84B2-48C1-8AE4-3E5704BE9BC7Q407646-20F641F0-D233-4481-B856-006648CD57A2Q408556-6BA97ED9-830A-41DB-A099-614FC2B57809Q411517-116C5EC6-0211-4D07-99B2-89897FC3538CQ411517-8B2A0072-5F8E-4B68-8C17-11F76ED55ED7Q413994-EA3AEC25-9E4E-41BD-BD84-37E2AA617C6CQ4781812-03044F53-97DA-4D24-87D4-40255F20D5B0Q48318-10E421EA-1864-47C9-A071-F656B6033E75Q48566671-FA26F43E-A85F-49D1-987D-B943F363B4CFQ4859684-684D0CDD-E55F-4B50-85B4-64C72119D765Q4859684-BFD9ABC7-FDFF-4741-BEE7-8E1AF82760ADQ546434-365ED534-344A-4D3A-B71C-281E2758DF75Q577377-195D6E9C-19F6-4DF8-8548-E5841B3D0CFEQ634959-AF01EFB9-F06C-4E74-84FB-EE942430BA4DQ6593346-8BBBF2DA-6576-40F9-9123-AEF1ACD49F0DQ794162-8576EAC4-EC24-4E6A-A0DF-5BE19210D374Q905952-33D057CE-3D59-4D07-8A38-61D7B8C7F455
P2175
Q29004876-DA901BEE-7F24-4531-A237-229AC14D5839Q29004881-1FE73F20-4EA5-46A5-8BB2-0B44324AD8D8Q29005749-4DAB6DC5-D7A2-4125-BF05-9AA25DAE65D1Q29005895-3A9A2D69-6EFD-4D46-ACC1-17AEC6C4FE2DQ29006048-BE441580-6650-419F-B995-0E91DDA80BFCQ29006146-8146BBF2-21F6-45A0-9D22-4F3A94DB766EQ29006485-1A2FAC34-F6D5-452D-8D72-E074C1626C9AQ29006591-4343DBBD-BB1E-4C82-BF3E-086C116EE4E9
P4044
Q26764956-A4D40930-A304-49C0-A91E-1FCE50FB13C1Q30588260-F04DBCC0-7E9C-4DB1-82A8-B91D2AE06179Q35071041-12DEC28C-7681-4E65-A32A-85008EB1FEF4Q35617544-61822259-6550-4DB4-B959-DA355A5B69FFQ35663108-5BB6C30B-363C-49EE-B1E8-AC3596CF9ACAQ37091331-F4BC1660-291A-46DD-A840-B1EE5C733807Q38637048-A9092FAB-AF91-4A7B-A049-DA92E21EFB33Q43947680-5CCC65BD-8C6E-412B-8047-D1873340190DQ47587175-8BD98FD1-C206-45D8-9E93-E34ABD6548A2Q55022142-61871658-488A-450B-A1D4-ABB64375F0FEQ61810990-1093B124-1C3E-4E10-9C75-3D7E06EA4B08Q64116734-6FA7271A-A105-4B76-9FB7-8FAEA7FA4317
P921
description
erhöhter Augeninnendruck ohne Sehnervschädigung
@de
eye disease that is characteri ...... ve damage or visual field loss
@en
name
Tăng nhãn áp
@vi
gordyndra llygadol
@cy
hipertensión ocular
@es
hipertensão ocular
@pt
hypertension oculaire
@fr
ocular hypertension
@en
okula hipertensio
@eo
okuläre Hypertension
@de
okulær hypertensjon
@nn
Глазная гипертензия
@ru
type
label
Tăng nhãn áp
@vi
gordyndra llygadol
@cy
hipertensión ocular
@es
hipertensão ocular
@pt
hypertension oculaire
@fr
ocular hypertension
@en
okula hipertensio
@eo
okuläre Hypertension
@de
okulær hypertensjon
@nn
Глазная гипертензия
@ru
altLabel
Ocular hypertension (disorder)
@en
hypertonie oculaire
@fr
فرط التوتر العيني
@ar
眼圧亢進
@ja
prefLabel
Tăng nhãn áp
@vi
gordyndra llygadol
@cy
hipertensión ocular
@es
hipertensão ocular
@pt
hypertension oculaire
@fr
ocular hypertension
@en
okula hipertensio
@eo
okuläre Hypertension
@de
okulær hypertensjon
@nn
Глазная гипертензия
@ru
P2176
P486
P6366
P672
P1692
P1748
P1995
P2176
P2892
P3827
ocular-hypertension
P4229
P486
P5270
MONDO:0006875
P6366
2776521421